Lit Matters 1: Albumin for Sepsis in the ED

Early concentrated albumin in sepsis did not raise 24-hour blood pressure over usual crystalloid care, but it did reduce fluid exposure, vasopressor use, and early organ dysfunction. For ED sepsis resuscitation, the signal is physiologic rather than practice-changing.

Albumin in Early Sepsis Resuscitation

• Physiologic rationale for albumin: Hyperoncotic 20% albumin aims to do more than expand volume, with proposed benefits in oncotic support, endothelial glycocalyx integrity, and antioxidant buffering during early septic hypoperfusion.
• ICARUS-ED primary result: The main endpoint was a miss: 24-hour systolic blood pressure was essentially unchanged despite early albumin, a useful reality check before adding it to routine ED sepsis care.
• Secondary hemodynamic signal: Albumin showed a modest early signal, with about 4 mmHg higher systolic pressure at 6 hours plus less total fluid by 72 hours, details we put in clinical context in the episode.
• Vasopressor and SOFA effects: Patients receiving albumin were less likely to need vasopressors at 24 and 72 hours and had better SOFA scores, suggesting possible organ-support benefit short of a hard outcome win.
• No mortality benefit yet: Mortality, ICU admission, and safety were not improved in a meaningful way, and the albumin arm actually stayed in hospital about 1.7 days longer for reasons that remain unclear.
• Practice implication today: Albumin is not ready for prime-time ED sepsis resuscitation; this pilot supports feasibility and helps identify who might benefit most, a selection question we get into in the chapter.